1. Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas.
- Author
-
Zhang LN, Cao X, Lu TX, Fan L, Wang L, Xu J, Zhang R, Zou ZJ, Wu JZ, Li JY, and Xu W
- Subjects
- Antibodies, Humans, Immunohistochemistry, Lymphoma, B-Cell metabolism, Lymphoma, Mantle-Cell metabolism, SOXC Transcription Factors biosynthesis, Biomarkers, Tumor analysis, Lymphoma, B-Cell diagnosis, Lymphoma, Mantle-Cell diagnosis, SOXC Transcription Factors analysis
- Abstract
Objectives: To determine whether SOX11 is a diagnostic marker of mantle cell lymphoma (MCL)., Methods: We analyzed SOX11 expression in 349 B-cell non-Hodgkin lymphomas (B-NHLs) via immunohistochemistry., Results: Nuclear staining of SOX11 was observed in 54 (93.1%) of 58 MCLs. We noticed that SOX11 protein was also expressed on the nuclei in 8 (21.6%) of 37 B-lymphoblastic lymphomas, 45 (32.6%) of 138 diffuse large B-cell lymphomas, 15 (44.1%) of 34 follicular lymphomas, 8 (30.8%) of 26 Burkitt lymphomas, 2 (10.0%) of 20 chronic lymphocytic leukemia/small cell lymphomas, and 3 (18.8%) of 16 marginal zone lymphomas., Conclusions: Although the positive rate of SOX11 expression in MCL was significantly higher than other B-NHLs (P < .001), polyclonal antibody targeting SOX11 is not able to identify MCL from B-NHLs because the nuclear staining of SOX11 was widely positive in B-NHLs.
- Published
- 2013
- Full Text
- View/download PDF